Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Apyx Medical (APYX) EPS (Weighted Average and Diluted) (2016 - 2024)

Apyx Medical filings provide 15 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.19 for Q2 2024.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 533.33% to -$0.19 in Q2 2024 year-over-year; TTM through Jun 2024 was -$0.82, a 74.47% decrease, with the full-year FY2023 number at -$0.54, up 19.4% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.19 in Q2 2024 for Apyx Medical, up from -$0.22 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.03 in Q2 2023 to a low of -$0.28 in Q4 2023.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.14 (2020), compared with a mean of -$0.14.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 81.25% in 2023 and later tumbled 533.33% in 2024.
  • Apyx Medical's EPS (Weighted Average and Diluted) stood at -$0.05 in 2020, then decreased by 20.0% to -$0.06 in 2021, then tumbled by 183.33% to -$0.17 in 2022, then crashed by 64.71% to -$0.28 in 2023, then surged by 32.14% to -$0.19 in 2024.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.19 (Q2 2024), -$0.22 (Q1 2024), and -$0.28 (Q4 2023) per Business Quant data.